Seaport-based biotech Bambusa Therapeutics has filed for a Bambusa Therapeutics IPO, submitting a Form S-1 registration statement to the U.S. Securities and Exchange Commission on Friday, Oct. 9. The company, whose principal executive offices are listed at 22 Boston Wharf Road in Boston, has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol BBTX.
The preliminary prospectus leaves the share count and price range blank, which is common for an initial filing. IPO research firm Renaissance Capital reported that the company filed to raise up to $100 million and that it had first filed confidentially on Aug. 3, 2026. BofA Securities, Evercore ISI, UBS Investment Bank and Cantor are named on the cover as the underwriters.
What Bambusa Therapeutics is developing
Bambusa describes itself in the filing as a clinical-stage company developing long-acting bispecific antibodies, single molecules designed to block two disease pathways at once, for immunology and inflammation. The company was formed on March 14, 2024, and acquired its two lead programs from BioNTech (Zhuhai) Pharmaceuticals R&D, a BioNTech subsidiary formerly known as Biotheus, according to the S-1.
Its lead candidate, BBT001, targets IL-4Rα and IL-31, pathways the company says address the inflammation and chronic itch of atopic dermatitis, the skin disease commonly called eczema. The filing says those pathways are already validated by approved drugs, naming Dupixent for IL-4Rα and Nemluvio for IL-31. BBT001 is in a global Phase 1 trial in the United States, Australia, Europe and New Zealand, a Phase 1a/1b trial in China, and a Phase 2a trial in China for chronic spontaneous urticaria, a type of chronic hives.
A second candidate, BBT002, targets IL-4Rα and IL-5. Renaissance Capital reported that it is in early trials for COPD, chronic rhinosinusitis with nasal polyps and asthma. Two preclinical programs, BBT003 and BBT004, are planned to enter clinical trials by the end of 2026 and 2027, respectively, according to the S-1.
Early eczema data and upcoming readouts
In July 2026, Bambusa reported topline results from 17 patients with moderate-to-severe atopic dermatitis who had not previously received similar biologics or JAK inhibitors and were treated for four weeks with an intravenous form of BBT001. As of the June 8 data cutoff, the company reported that at Week 6, the placebo-adjusted share of patients achieving at least a 50 percent improvement on the Eczema Area and Severity Index was 82 percent, and 64 percent for at least a 75 percent improvement. The company also said no cases of conjunctivitis were reported and that it believes quarterly maintenance dosing will be possible.
The filing lists several additional BBT001 readouts expected in the first half of 2027, including 12-week data in both treatment-naive and previously treated eczema patients and 14-week data in chronic hives. Bambusa also plans to begin start-up work on a Phase 2b dose-ranging trial of an under-the-skin formulation by the end of 2026.
Bambusa Therapeutics IPO financials
Bambusa has no product revenue. The S-1 reports net losses of $41.1 million in 2025 and $13.7 million from its inception through 2024, plus $22.4 million in the first half of 2026, up from $14.7 million a year earlier. Its accumulated deficit was $77.2 million as of June 30, 2026, when it held $71.5 million in cash, cash equivalents and marketable securities.
The company states that those funds are not expected to cover operations for at least 12 months and that management has concluded there is substantial doubt about its ability to continue as a going concern without new capital. It plans to use IPO proceeds mainly to advance BBT001 and BBT002 into Phase 2b trials.
Before filing, Bambusa raised about $9.0 million in a Series Seed Plus round in August 2024, $53.3 million and $35.6 million in Series A-1 closings in February and June 2025, and $32.1 million and $1.0 million in Series A-2 closings in October 2025 and January 2026, the S-1 shows. As of Sept. 30, 2026, it had 30 full-time employees, 24 in research and development. Its Boston headquarters consists of about 250 square feet of office space under a services agreement that runs to April 28, 2027. Chief Executive Officer Shanshan Xu, who holds an M.D., a Ph.D. and an MIT MBA, is also president and board chair.
Our Take
This section is analysis and opinion, separate from the reporting above.
Bambusa fits a familiar Boston biotech pattern: licensed molecules, a lean team and an early data package strong enough to open the IPO window. The July eczema numbers are eye-catching, but they come from 17 patients over a short course, and the filing itself warns that early results may not hold up in larger trials. The real test is the set of 12-week readouts in the first half of 2027.
The going-concern language matters. With $71.5 million in cash at mid-year and losses rising, this offering is less a victory lap than a funding requirement, so pricing and demand will tell us how much investors are willing to pay for a crowded eczema market where Dupixent already dominates. For Boston, a 250-square-foot headquarters means the listing adds a ticker more than jobs or lab space for now. Still, a successful debut would be another sign that the region’s life sciences companies can reach public markets, following moves like Lundbeck’s U.S. headquarters move to Boston and big-pharma deals such as the Novartis-Abogen mRNA agreement. For more on the space these companies compete for, see our look at lab development in Boston.